[go: up one dir, main page]

AU2001280812A1 - Gsk3 polypeptides - Google Patents

Gsk3 polypeptides

Info

Publication number
AU2001280812A1
AU2001280812A1 AU2001280812A AU8081201A AU2001280812A1 AU 2001280812 A1 AU2001280812 A1 AU 2001280812A1 AU 2001280812 A AU2001280812 A AU 2001280812A AU 8081201 A AU8081201 A AU 8081201A AU 2001280812 A1 AU2001280812 A1 AU 2001280812A1
Authority
AU
Australia
Prior art keywords
gsk3
polypeptides
amino acid
substituted amino
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001280812A
Inventor
Maria Calderon-Cacia
Doris G. Coit
Eric Y. Fang
John A Hall
Stephen D. Harrison
Angelica Medina-Selby
Steven H. Nguyen
Ziyang Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2001280812A1 publication Critical patent/AU2001280812A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01037—Protein kinase (2.7.1.37)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)

Abstract

The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3± and GSK3² polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.
AU2001280812A 2000-07-27 2001-07-25 Gsk3 polypeptides Abandoned AU2001280812A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22124200P 2000-07-27 2000-07-27
US60/221,242 2000-07-27
PCT/US2001/023539 WO2002010357A2 (en) 2000-07-27 2001-07-25 Gsk3 polypeptides

Publications (1)

Publication Number Publication Date
AU2001280812A1 true AU2001280812A1 (en) 2002-02-13

Family

ID=22826991

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001280812A Abandoned AU2001280812A1 (en) 2000-07-27 2001-07-25 Gsk3 polypeptides

Country Status (10)

Country Link
US (6) US6465231B2 (en)
EP (2) EP1319064B1 (en)
JP (1) JP2004504838A (en)
CN (1) CN1276974C (en)
AT (1) ATE450604T1 (en)
AU (1) AU2001280812A1 (en)
DE (2) DE60131550T2 (en)
ES (1) ES2295191T3 (en)
PT (2) PT1319064E (en)
WO (1) WO2002010357A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4122216B2 (en) * 2000-09-19 2008-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Characterization of GSK-3β protein and methods of use thereof
WO2003068932A2 (en) 2002-02-11 2003-08-21 Chiron Corporation Method for crystallizing human gsk3 and novel crystal structure thereof
WO2005083111A1 (en) * 2004-02-26 2005-09-09 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glycogen synthase kinase 3 alpha (gsk3a)
US20060127388A1 (en) * 2004-12-10 2006-06-15 Wyeth Variants of glycogen synthase kinase 3 and uses thereof
US20100105745A1 (en) * 2005-01-04 2010-04-29 Toshinari Minamoto Suppression of cancer and method for evaluating anticancer agent based on the effect of inhibiting gsk3 beta
EP1845094A4 (en) * 2005-01-04 2009-12-16 Univ Kanazawa Nat Univ Corp METHOD FOR TUMOR SUPPRESSION AND EVALUATION OF ANTIBACTERIES BASED ON A GSK3 BETA-INHIBITING EFFECT
NZ564285A (en) * 2005-06-20 2010-03-26 Decode Genetics Ehf Genetic variants in the TCF7L2 gene as diagnostic markers for risk of type 2 diabetes mellitus
CA2618613A1 (en) 2005-08-09 2007-02-22 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
EP3249054A1 (en) 2012-12-20 2017-11-29 Biomatrica, INC. Formulations and methods for stabilizing pcr reagents
EP3007556B1 (en) 2013-06-13 2020-05-20 Biomatrica, INC. Cell stabilization
WO2015155738A2 (en) 2014-04-09 2015-10-15 Christopher Rudd Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
EP3942931A1 (en) 2014-06-10 2022-01-26 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
KR20250047404A (en) 2015-12-08 2025-04-03 바이오매트리카 인코포레이티드 Reduction of erythrocyte sedimentation rate
CN117384983B (en) * 2023-12-07 2024-02-23 中国中医科学院中药研究所 Preparation method of GSK-3 alpha inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591872A (en) * 1993-08-09 1997-01-07 The University Of Iowa Research Foundation Autoinducer molecule
US5961979A (en) * 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5693496A (en) * 1994-06-20 1997-12-02 Merck & Co., Inc. DNA encoding the mouse and human PH30 beta chain protein
US5698396A (en) * 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US6057117A (en) 1996-04-04 2000-05-02 Chiron Corporation Identification and use of selective inhibitors of glycogen synthase kinase 3
EP1082430A1 (en) * 1998-05-28 2001-03-14 ZymoGenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
JP4533534B2 (en) 1998-06-19 2010-09-01 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Inhibitor of glycogen synthase kinase 3
US6057218A (en) * 1999-05-07 2000-05-02 Vanguard International Semiconductor Corporation Method for simultaneously manufacturing poly gate and polycide gate

Also Published As

Publication number Publication date
US7135321B2 (en) 2006-11-14
US20070249004A1 (en) 2007-10-25
US20080182313A1 (en) 2008-07-31
EP1914305A1 (en) 2008-04-23
JP2004504838A (en) 2004-02-19
PT1914305E (en) 2010-01-29
DE60131550T2 (en) 2008-10-23
EP1319064B1 (en) 2007-11-21
US6465231B2 (en) 2002-10-15
US20060088932A1 (en) 2006-04-27
DE60131550D1 (en) 2008-01-03
EP1319064A2 (en) 2003-06-18
US7195886B2 (en) 2007-03-27
WO2002010357A3 (en) 2003-04-03
US20050048511A1 (en) 2005-03-03
WO2002010357A2 (en) 2002-02-07
CN1468302A (en) 2004-01-14
PT1319064E (en) 2008-02-29
DE60140707D1 (en) 2010-01-14
ES2295191T3 (en) 2008-04-16
US7807430B2 (en) 2010-10-05
US7361484B2 (en) 2008-04-22
US6716624B2 (en) 2004-04-06
EP1914305B1 (en) 2009-12-02
ATE450604T1 (en) 2009-12-15
CN1276974C (en) 2006-09-27
US20020082408A1 (en) 2002-06-27
US20030077798A1 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
AU2001280812A1 (en) Gsk3 polypeptides
GB0117326D0 (en) Napthoquinone-type inhibitors of protein aggregation
BR9713186A (en) 1,3-diheterocyclic metalloprotease inhibitors
AU3986493A (en) Protease and related DNA compounds
WO2004064778A3 (en) 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
DE60231804D1 (en) USE OF HEPCIDINE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF IRON HOMEOSTASTE DISORDER
ATE231496T1 (en) SACCHARINE DERIVATIVES AS PROTEOLYTIC ENZYMIN HIBITORS
FI925787A0 (en) PROTEOLYTICAL ENZYMERS SACKARINDERIVATINHIBITORER
BR9812837A (en) Process for making a compound, and, compound
AU7934900A (en) Method of screening for inhibitors of asp2
WO2003039454A8 (en) Beta-secretase inhibitors and methods of use
DE60025008D1 (en) DETERMINATION OF ADRENOMEDULLIN-BINDING PROTEINS
DK0948604T3 (en) Screening methods for compounds that bind to the PYK2 polypeptide
HUP9901751A3 (en) Novel substituted n-methyl-n-(4-(piperidin-1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases
WO1998020034A3 (en) Novel serine protease inhibitor nucleic acid molecules, proteins and uses thereof
BR0112123A (en) Compound
DE69809785D1 (en) USE OF A RETINOIDIDE IN VIVO INCREASING THE UNCOVERING OF THE UCP2 PROTEIN
DE59609977D1 (en) TRAPIDIL FOR USE IN THE THERAPY OF IMMUNO-MODULATABLE INFLUENCES
BR9915572A (en) Process of treatment of sickle cell disease and thalassemia
ATE311901T1 (en) USE OF TGF-BETA INHIBITORS TO TREAT CEREBRAL DISEASES
ATE391915T1 (en) USE OF GRF-1 PROTEIN TO SELECT MOLECULES
FI972673A7 (en) 4,4-(disubstituted)cyclohexan-1-ol monomers and related compounds
ATE180478T1 (en) USE OF SUBSTITUTED 6-AMINO-4H-PYRANES
WO2004047854A3 (en) Methods for the treatment of alzheimers disease and compositions therefore
DE60203726D1 (en) TOPICAL COMPOSITION CONTAINING BRUCIN AND ITS USE FOR THE TREATMENT OF SKIN DAMAGE